An Engineered Influenza a Virus Expressing the Co-Stimulator OX40L as an Oncolytic Agent Against Hepatocellular Carcinoma.

ABSTRACT:

Background

Oncolytic virus (OV) therapy has emerged as a promising novel form of immunotherapy. Moreover, an increasing number of studies have shown that the therapeutic efficacy of OV can be further improved by arming OVs with immune-stimulating molecules.

Methods

In this study, we used reverse genetics to produce a novel influenza A virus, termed IAV-OX40L, which contained the immune-stimulating molecule OX40L gene in the influenza virus nonstructural (NS1) protein gene. The oncolytic effect of IAV-OX40L was explored on hepatocellular carcinoma (HCC)HCC cells in vitro and in vivo.

Results

Hemagglutination titers of the IAV-OX40L virus were stably 2⁷-2⁸ in specific-pathogen-free chicken embryos. The morphology and size distribution of IAV-OX40L

SUBMITTER: Yang H 

PROVIDER: S-EPMC10787515 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature